GAITHERSBURG, Md., March 06, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, announced today that Bill Enright, President and Chief Executive Officer, will provide a corporate overview at the 30th Annual ROTH Conference and the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium.
| 30th Annual ROTH Conference Presentation Details | ||
| Date: | Tuesday, March 13 | |
| Time: | 7:00pm Eastern Time/4:00pm Pacific Time | |
| Location: | The Ritz Carlton Orange County, Newport Beach, California – Salon 6 | |
| B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium (CHIPS) | ||
| Date: | Saturday, March 17 | |
| Time: | 8:30am China Time/7:30pm Eastern Time – Room A | |
| Location: | Intercontinental Hotel, Hangzhou, China | |
About Altimmune
Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease including, NasoVAX, a Phase 2 seasonal influenza vaccine candidate, and HepTcell, a Phase 1 immunotherapeutic candidate for the potential cure of chronic hepatitis B. The company also has two United States government funded, next-generation anthrax vaccine candidates that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines.
Contacts:
Bill Enright
President and CEO
Phone: 240-654-1450
Email: enright@altimmune.com
Ashley Robinson
Managing Director LifeSci Advisors
Phone: 617-535-7742
Email: arr@lifesciadvisors.com